Détails sur le projet
Description
PROJECT SUMMARY
The enzymatic modification of proteins through tyrosine phosphorylation is a common mechanism
for relaying information in animal cells. Tyrosine kinases act in a signal-responsive manner to
phosphorylate specific proteins at tyrosine residues, and the opposing tyrosine phosphatases
dephosphorylate proteins to dynamically regulate signals. Tyrosine phosphorylation is essential to many
biological processes in healthy cells, and the dysregulation of tyrosine phosphorylation is a common
feature of many diseases, most notably cancers. Over the past few decades, we have developed an
extensive understanding of tyrosine kinase function and regulation, but our knowledge of tyrosine
phosphatases lags behind. This disparity is partly due to the fact that it is easier to develop drugs that
target tyrosine kinases than tyrosine phosphatases, and the therapeutic potential of tyrosine kinases has
motivated the development of robust tools to study their structure, biochemistry, and biology.
The overarching goals of my lab are to understand, at the molecular level, how tyrosine
phosphatases select substrate proteins to dephosphorylate, how they are regulated through dynamic
changes in their structure, and how they contribute to healthy and disease-associated signaling. Over
the next five years, my group will devise new techniques to study tyrosine phosphatases. We are currently
developing a high-throughput biochemical platform to rapidly identify and compare the substrate
sequence preferences of tyrosine phosphatases. These analyses will be conducted in parallel with
proximity-labeling experiments in live cells to tag the interaction partners of tyrosine phosphatases for
identification by mass spectrometry. Together, these approaches will allow us to map the substrates of
tyrosine phosphatases and help define the signaling roles of these enzymes. We are also developing
methods to rapidly characterize the functional effects of all possible point mutations in a tyrosine
phosphatase. These mutational screens will allow us to identify new modes of regulation, pinpoint the
functional consequences of disease-associated mutations, and map likely drug-resistance mutations that
may arise to phosphatase-targeted cancer therapies.
We are broadly interested in two areas of signaling biology: diseases where tyrosine
phosphatases are mutated and/or dysregulated, and the activation of immune T cells. As we develop
new biochemical tools, we will initially apply these tools to the tyrosine phosphatase SHP2, which plays
a causal role in several congenital diseases and cancers, and is also critical to normal signaling in many
cell types, including T cells. Our work will clarify the signaling functions of SHP2, connect known
mutations to specific phenotypes, and help guide the development of SHP2-targeted therapies. In the
long-term, we will apply our novel approaches to other tyrosine phosphatases.
Statut | Terminé |
---|---|
Date de début/de fin réelle | 7/1/20 → 6/30/22 |
Financement
- National Institute of General Medical Sciences: 105 430,00 $ US
- National Institute of General Medical Sciences: 7 134,00 $ US
- National Institute of General Medical Sciences: 898 522,00 $ US
- National Institute of General Medical Sciences: 392 979,00 $ US
Keywords
- Bioquímica
Empreinte numérique
Explorer les sujets de recherche abordés dans ce projet. Ces étiquettes sont créées en fonction des prix/bourses sous-jacents. Ensemble, ils forment une empreinte numérique unique.